Table 4

Impact of HSV-2 seropositivity on viral loada
Study Population N HSV2 Ascertainment Outcome: VIRAL LOAD (in log10 copies/mL)
Outcome HSV2 pos HSV2 neg Difference Effectb
Studies in acute HIV seroconverters
Barnabas 2011 HIV seroconverters, Americas 88 Serology: WB VL setpoint (mean of 8 & 12 week post-infection VL)c +0.3 (95% CI = −0.1,0.7) Referent “No significant difference”
Cachay 2007 Male HIV seroconverters, USA 294 Serology: Focus + WB VL over median of ~200 days NR NR Difference “close to zero”
Cachay 2008 Male HIV seroconverters, USA 9 Seroconversion to HSV2 by WB Change in VL after vs. before HSV-2 sero-conversion over 779d +0.17 (range −1.58, 0.49) Reference: Before seroconversion p = 0.57
Studies in chronic HIV infection
Crum-Cianflone 2006 USA 271 Serology: Focus Change in VL at 1 year +0.17 +0.08 +0.1, p = 0.61
221 Change in VL at 3 years +0.46 −0.09 +0.6, p = 0.44 ↑?
Roxby 2011 Postpartum women, Kenya 296 Serology: Focus Change in VL over mean 18 months NR NR No difference

aCI = confidence interval, GUD = genital ulcer disease, MSM = men who have sex with men, OR = odds ratio, SD = standard deviation, VL = viral load, WB = Western Blot.

bArrows show directions of association with HSV-2; ‘?’ denotes borderline statistical significance or clinically significant differences not meeting statistical significance.

cBased in part on imputed data as 47% of VL observations missing.

Tan et al.

Tan et al. BMC Infectious Diseases 2013 13:502   doi:10.1186/1471-2334-13-502

Open Data